Bajaj Healthcare Limited (BAJAJHCARE) - Net Assets
Based on the latest financial reports, Bajaj Healthcare Limited (BAJAJHCARE) has net assets worth Rs5.33 Billion INR (≈ $57.64 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs9.23 Billion ≈ $99.84 Million USD) and total liabilities (Rs3.90 Billion ≈ $42.20 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore BAJAJHCARE total asset value for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs5.33 Billion |
| % of Total Assets | 57.73% |
| Annual Growth Rate | 21.15% |
| 5-Year Change | 62.26% |
| 10-Year Change | 438.38% |
| Growth Volatility | 35.68 |
Bajaj Healthcare Limited - Net Assets Trend (2011–2026)
This chart illustrates how Bajaj Healthcare Limited's net assets have evolved over time, based on quarterly financial data. Check tangible net worth ratio of Bajaj Healthcare Limited to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Bajaj Healthcare Limited (2011–2026)
The table below shows the annual net assets of Bajaj Healthcare Limited from 2011 to 2026. For live valuation and market cap data, see Bajaj Healthcare Limited (BAJAJHCARE) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2026-03-31 | Rs5.33 Billion ≈ $57.64 Million |
+14.34% |
| 2025-03-31 | Rs4.66 Billion ≈ $50.41 Million |
+67.47% |
| 2024-03-31 | Rs2.78 Billion ≈ $30.10 Million |
-24.29% |
| 2023-03-31 | Rs3.68 Billion ≈ $39.76 Million |
+11.93% |
| 2022-03-31 | Rs3.28 Billion ≈ $35.52 Million |
+27.12% |
| 2021-03-31 | Rs2.58 Billion ≈ $27.95 Million |
+70.45% |
| 2020-03-31 | Rs1.52 Billion ≈ $16.40 Million |
+17.43% |
| 2019-03-31 | Rs1.29 Billion ≈ $13.96 Million |
+13.64% |
| 2018-03-31 | Rs1.14 Billion ≈ $12.29 Million |
+14.76% |
| 2017-03-31 | Rs990.00 Million ≈ $10.71 Million |
+11.70% |
| 2016-03-31 | Rs886.32 Million ≈ $9.59 Million |
+126.85% |
| 2015-03-31 | Rs390.72 Million ≈ $4.23 Million |
+23.81% |
| 2014-03-31 | Rs315.57 Million ≈ $3.41 Million |
+6.66% |
| 2013-03-31 | Rs295.85 Million ≈ $3.20 Million |
-3.45% |
| 2012-03-31 | Rs306.41 Million ≈ $3.31 Million |
+2.17% |
| 2011-03-31 | Rs299.91 Million ≈ $3.24 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Bajaj Healthcare Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Rs168.31 Million | 3.16% |
| Other Components | Rs5.16 Billion | 96.84% |
| Total Equity | Rs5.33 Billion | 100.00% |
Bajaj Healthcare Limited Competitors by Market Cap
The table below lists competitors of Bajaj Healthcare Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Amber International Holding Limited
NASDAQ:AMBR
|
$120.10 Million |
|
Jalles Machado S/A
SA:JALL3
|
$120.11 Million |
|
Rav Bariach 08 Industries Ltd
TA:BRIH
|
$120.17 Million |
|
Cosmax Nbt Inc
KQ:222040
|
$120.21 Million |
|
Merit Turizm Yatirim ve Isletme AS
IS:MERIT
|
$120.02 Million |
|
Servotronics Inc
NYSE MKT:SVT
|
$120.00 Million |
|
YFC-BonEagle Electric Co Ltd
TWO:6220
|
$119.97 Million |
|
vTv Therapeutics Inc
NASDAQ:VTVT
|
$119.97 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bajaj Healthcare Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 4,661,642,000 to 5,330,023,000, a change of 668,381,000 (14.3%).
- Net income of 157,661,000 contributed positively to equity growth.
- Dividend payments of 31,583,000 reduced retained earnings.
- New share issuances of 526,080,000 increased equity.
- Other comprehensive income decreased equity by 161,208,999.
- Other factors increased equity by 177,431,999.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs157.66 Million | +2.96% |
| Dividends Paid | Rs31.58 Million | -0.59% |
| Share Issuances | Rs526.08 Million | +9.87% |
| Other Comprehensive Income | Rs-161.21 Million | -3.02% |
| Other Changes | Rs177.43 Million | +3.33% |
| Total Change | Rs- | 14.34% |
Book Value vs Market Value Analysis
This analysis compares Bajaj Healthcare Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.96x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 29.69x to 1.96x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-03-31 | Rs11.11 | Rs329.80 | x |
| 2012-03-31 | Rs11.35 | Rs329.80 | x |
| 2013-03-31 | Rs10.96 | Rs329.80 | x |
| 2014-03-31 | Rs11.69 | Rs329.80 | x |
| 2015-03-31 | Rs14.47 | Rs329.80 | x |
| 2016-03-31 | Rs32.83 | Rs329.80 | x |
| 2017-03-31 | Rs35.95 | Rs329.80 | x |
| 2018-03-31 | Rs41.17 | Rs329.80 | x |
| 2019-03-31 | Rs46.78 | Rs329.80 | x |
| 2020-03-31 | Rs54.93 | Rs329.80 | x |
| 2021-03-31 | Rs93.63 | Rs329.80 | x |
| 2022-03-31 | Rs119.02 | Rs329.80 | x |
| 2023-03-31 | Rs133.23 | Rs329.80 | x |
| 2024-03-31 | Rs100.86 | Rs329.80 | x |
| 2025-03-31 | Rs144.77 | Rs329.80 | x |
| 2026-03-31 | Rs168.02 | Rs329.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bajaj Healthcare Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.96%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.58%
- • Asset Turnover: 0.66x
- • Equity Multiplier: 1.73x
- Recent ROE (2.96%) is below the historical average (9.10%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 14.91% | 3.73% | 1.16x | 3.45x | Rs14.74 Million |
| 2012 | 2.12% | 0.46% | 1.16x | 3.96x | Rs-24.14 Million |
| 2013 | -3.57% | -0.62% | 1.30x | 4.43x | Rs-40.14 Million |
| 2014 | 6.25% | 0.96% | 1.41x | 4.61x | Rs-11.84 Million |
| 2015 | 19.23% | 3.44% | 1.50x | 3.73x | Rs36.08 Million |
| 2016 | 9.25% | 3.68% | 1.07x | 2.36x | Rs-6.63 Million |
| 2017 | 7.90% | 3.39% | 1.05x | 2.21x | Rs-20.75 Million |
| 2018 | 13.37% | 5.29% | 1.07x | 2.36x | Rs38.25 Million |
| 2019 | 12.63% | 5.05% | 1.21x | 2.07x | Rs34.00 Million |
| 2020 | 16.65% | 7.02% | 1.10x | 2.15x | Rs100.76 Million |
| 2021 | 32.16% | 12.67% | 1.25x | 2.03x | Rs572.68 Million |
| 2022 | 21.73% | 10.51% | 0.94x | 2.20x | Rs385.37 Million |
| 2023 | 11.70% | 6.66% | 0.72x | 2.45x | Rs62.55 Million |
| 2024 | -30.10% | -17.70% | 0.62x | 2.75x | Rs-1.12 Billion |
| 2025 | 8.47% | 7.28% | 0.65x | 1.79x | Rs-71.21 Million |
| 2026 | 2.96% | 2.58% | 0.66x | 1.73x | Rs-375.34 Million |
Industry Comparison
This section compares Bajaj Healthcare Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $13,357,975,882
- Average return on equity (ROE) among peers: 16.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bajaj Healthcare Limited (BAJAJHCARE) | Rs5.33 Billion | 14.91% | 0.73x | $120.06 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $923.46 Million | 6.27% | 1.10x | $24.98 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $2.51 Billion | 24.60% | 2.39x | $410.81 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $2.31 Million | -8.08% | 0.08x | $672.35 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $6.40 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $2.29 Billion | 22.16% | 1.28x | $4.71 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $1.15 Billion |
| Alkem Laboratories Limited (ALKEM) | $49.85 Billion | 12.66% | 0.54x | $7.27 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $1.29 Billion | 15.52% | 0.29x | $162.96 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $8.85 Billion | 31.98% | 0.86x | $1.76 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $18.33 Billion | 30.59% | 1.61x | $10.32 Billion |
About Bajaj Healthcare Limited
Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in India and internationally. The company offers active pharmaceutical ingredient in various therapeutic categories, including anti-diabetic, antibiotic, … Read more